Innovate the way we see life

Tomocube

Disclaimer

This material has been prepared by Tomocube, Inc. (“the Company”) for informational purposes in investor presentations. The forward-looking statements contained herein have not been independently verified. These statements relate to future events and include the Company’s expectations regarding its future operational and financial performance. Terms such as “expected,” “prospects,” “plans,” “anticipated,” “(E),” and similar expressions indicate such forward-looking content.

These forward-looking statements are subject to uncertainties arising from changes in the business environment, and actual performance may differ materially from what is described herein. Such outlooks are based on the Company’s current circumstances and strategies as of the date of this presentation and may change without prior notice due to market conditions or internal decisions.

The Company and its employees assume no responsibility or liability, including negligence or otherwise, for any loss arising from the use of this material. This document does not constitute an offer to purchase, sell, or subscribe for any securities and should not form the basis of any investment decision or agreement.

Investors should base their investment decisions solely on the Company’s official public filings with the Financial Supervisory Service.

Tomocube

Table of contents



Tomocube

Paradigm Shift in Cell Analysis

- Growth drivers: 3D Biology & Regenerative Medicine

Core: 3D label-free measurement & AI-enabled analysis of living cells, tissues, and organoids

Holotomography: Real-time, high-resolution, label-free 3D analysis of live cells

Unmet Needs Addressed by Holotomography

•• Fulfilling Unmet Needs in the Advanced Biomedical Sector

Conventional



Mitigates cell damage and deformation from fluorescent dyes



Typically, cells must be fixed, sectioned, and stained for structural observation

Unsuitable for therapeutic application

Impossible to conduct long term live cell analysis

VS

HT("Holotomography")



Label free imaging and cell analysis without any cell damage or loss



Applicable for therapeutic purposes

Long-term 3D observation of live cells possible

Transformative Effects

Exclusive solution for Cell biology & Regenerative medicine

Sample preprocessing	Not Required
Label-free 3D imaging analysis	First in Class
Unlimited, prolonged cell analysis	First in Class
Measurable sample thickness	↑ 5x

Setting new standards in cell analysis through Holotomography

•• Just as CT Transformed Diagnosis, HT is Poised to Transform Bioanalysis

CT
(Computed tomography)



Combines X-ray images from various angles to reconstruct 3D human structures

↳ CT A standardized technology for Medical diagnostics and treatment

	Similarity	
X-ray	Light source	Laser, LED
Human	Specimen	Cells, tissues
X-ray absorption	Image contrast	Refractive index
Motor	Light modulator	DMD

HT
(Holotomography)



Combines 2D holograms from various angles to reconstruct 3D cellular structures

↳ HT Standardization for bio-analysis technology

Leading Advanced Bio/Medical Industry

•• Pioneering Holotomography: From Innovation to Global Commercialization

Paradigm Shift in Bioimaging

The Evolution of Cell Imaging in the Era of Bio-Analysis Transformation

17th century	Development of light microscopy	20th century	Advances in Cell biology	21st century	Molecular cell Biology and diagnostics
Brightfield microscopy		Phasecontrast microscopy		Fluorescence microscopy	
ZEISS		OLYMPUS Nikon Leica		ThermoFisher Sartorius GE Healthcare	

3D Biology & Regenerative Medicine

3D Cell Structure Measurement & Analysis



“ Major Developer of Holotomography Technology ”

Tomocube

Cancer cell Organoid

Label-free 3D Live Cell Imaging

Cellular Responses and Recovery from High Level of Reactive Oxygen Species (ROS)

Tomocube



- Cell line: Hep3B
- Microscope: HT-X1
- Observation duration: 4.5 hr
- Time interval: 20 sec
- Chip: ibidi μ-Slide I Luer
- Flow rate: 0.23 μL/min

Cancer cell

Organoid

Label-free 3D live cell imaging

Tomocube

Unveiling the unseen: 3D Organoid visualization



Chapter 1.

Why Holotomography (HT)

Tomocube

01. Key Advantages of Holotomography

•• Establishing a Competitive Business Model Through Proprietary Hardware, Software, and AI solutions

Holotomography Platform

Hardware

3D Label-Free Imaging for Cell Analysis
HT Imaging Systems & Consumables
(Primary data generation platform with recurrent revenues)

Software



Subscription-based Image Analysis Software

(Recurrent subscription revenues)

AI



AI-based HT Image Analysis & Biomarker Discovery Service

(Custom development revenues with prospects of IP generation and proprietary biomarker discoveries)

Optimized for ultra high-resolution live cell imaging
(Label-free, minimized phototoxicity)

+

High-speed imaging data analysis

+

Quantitative data
(unbiased, standardized, reproducible results)

Total Solution Provider for HT Imaging and Analysis

02. HT Platform (1) Hardware

•• Establishing a Standard Protocol for 3D Label-Free Imaging

Unmet Needs

Limitations of Labeling



Fluorescent Excitation Induces Phototoxicity, Causing Cellular Damage and Functional Alteration

Limitations of 2D cell analysis

Challenging to Analyze Complex 3D Cellular Structures, Leading to Reduced Accuracy and Reliability

Hardware Competencies

Enables Observation of Cells in Their Native State Without Compromising Viability or Function



Observes intracellular organelles Label-free, based on precise refractive index measurement

Accurate 3D Cellular Analysis of Thick Tissues, Organoids, and Complex Samples



No sectioning for thick tissues (< 150 μm)

Allows comprehensive structural analysis of entire cells

Maximizes cell survival with minimal structural impact

Enables extended cell Imaging over time

02. HT Platform (2) Software

•• From Custom Solutions to an Integrated Analysis Platform

Software Competencies

Demand-Based Solution Development

2017 — **TomoStudio**



Visualization of 3D HT data and single-cell analysis

2019 — **Lipid Analysis**



Targeted analysis optimized for specific conditions

“Expanded application areas through AI model-based software”

2022 — **TomoAnalysis 1.0**



- AI Model-Based Cell Organelle Analysis
- Rule-based multi cell analysis
- Applying uniform logics to big data

2024 — **TomoAnalysis 2.0**



- Real-Time 3D Visualization
- Manageable Analysis Logic System
  - 120 Rule-based modules
  - 7 AI-based modules
- 33 Application-Specific Algorithms

AI-based software for cell and organelle analysis

02. HT Platform (3) AI

•• World-Leading AI-Powered Analysis Platform for HT Imaging and Biomarker Discovery

01

Quality Improvement via AI

Maximizing HT imaging definition & reconstruction speed



Up to 10x Reconstruction speed improvement

Up to 2x Definition

Solving laser speckle, Low SNR

02

Automated Cell/Organelle Segmentation

Automated quantitative analysis of large 3D images captured by HT



Machine Learning
+
Deep Learning
+
Code-less



03

Label-Free Cell Type & State Differentiation

Differentiates types and states of label-free cells using AI



Sepsis



19 bacteria types

99.9% Accuracy rate powered by AI analysis[2]

04

Virtual digital staining technology

Simulated staining extracted from HT images of non-stained cells



97% Extraction accuracy for 3D digital dyes[3]

+ 6 channels # of simultaneous 3D dye extraction

Google AI Exceeding Google AI and Allen Institute's capabilities

Reference 1 : J. Park et al., *Nature Methods* 20, 1645 (2023)
Reference 2 : G Kim et al. *Light: Science & Applications* 11, 190 (2022)
Reference 3 : Y. Jo et al., *Nature Cell biology* 23, 1329 (2021)

03. Distinct Competitive Advantages: Holotomography Comparison

- Tomocube: Defining the History of Holotomography

HT Technology Paradigm Shifts & Milestones



	1st Generation	2nd Generation	Future
Category	1st Gen HT (Competitor)	2nd Gen HT (Tomocube)	Future HT (Tomocube)
Model	3D Explorer	HT-X1 (2022 2H) / HT-X1 Plus (2024 2H) / HT-X1 mini (2025 2H)	HT-X1 Max (Planned 2026; currently under client testing)
Pros	High resolution	High resolution& SNR(Signal to Noise Ration) System stability with quantitative measurement	2x +a depth improvement from previous models Able to scan thicker organoids
Cons	Unstable, 3D measurement only for monolayered cell	Increased capital expenditure (excluding mini)	-
Maximum resolution	250 nm	150 nm	124 nm
Depth	30 μm	150 μm	Max 500 μm
Light source	Laser	LED (single wavelength)	LED (Multiple wavelengths)

03. Distinct Competitive Advantages: Cell Analysis Technology Comparison

•• Setting the Benchmark in Cell Analysis: Tomocube vs. Competitors

Necessary Specs



Comparison with Other Optical Devices

Category	3D Imaging	Resolution	Multimodal Imaging	Thickness	Label-free	Quantitative	Artificial Intelligence
Tomocube (Korea) HT (2nd Gen)	●	●	●	●	●	●	●
S*** (Germany)** Bright-field microscopy			○		△	△	
S*** (Japan)** Optical coherence tomography	○			○	○		
N** (Japan)** Confocal microscopy	○	○	○	△			
Z**(Germany)** Light sheet microscopy	○	△	○	○			△
M***** (USA)** High speed confocal microscopy	○	○	○	△		△	△
N**** (Swiss)** HT (1st Gen)	○	○	△		○	△	△

04. Externally Validated Technology with robust IP protection

92 Granted and Pending Patents; Domestic & International Recognition

- 2005
  - Foundational research in label-free holography
  - Early cell measurement and analysis
- 2010
  - Research in HT precision optical measurement technology
  - established quantitative cell analysis capabilities
- 2015 : Company Establishment
  - Developed holographic HT wavefront control technology
- 2017 : Released HT-2H
  - Developed AI-based HT imaging analysis technology
- 2022 : Release HT-X1
  - Initiated research on white light HT technology
  - Initiated R&D on industrial reflective HT technology

Patents related to core tech

R&D History	18 years
Publications	63
R&D Costs	KRW 19.8 bn.
domestic patents pending	16
domestic patents granted	26
international patents pending	26
international patents granted	24
Total patents	92

Awards and Recognitions

IR52 Jang Young-shil Award
Nov. '17 / Min. of Science and ICT

Microscopy Innovation Award
2019, 2025 / Microscopy Society of America

Best Life Science Product Finalist
2023 / SelectScience

- Top 10 Mechanical Technologies(2016)
- PRISM Awards Finalist (2018)
- Awarded by the Min. of Science and ICT, South Korea (2021)
- Awarded by the Min. of SMEs and Startups, South Korea (2021)
- Awarded by "Korea Innovative Startup" (2022)

Chapter 2.

Expanding the applications of HT

01. Tomocube's Target Market
02. Opportunity # 1 Organoids
    Opportunity # 2 In Vitro Fertilization
    Opportunity # 3 Cell Therapies
    Opportunity # 4 Drug Development
    Opportunity # 5 Non-Bio Industrial Applications

Tomocube

01. Tomocube's Target Market

3D Biology & Regenerative Medicine Market Growth

Market Size Projection

2027 Approx. 120 trillion KRW + α

Organoids

Organoid analysis in live conditions needed for toxicity evaluation and disease modeling



In Vitro Fertilization (IVF)

Non-invasive selection technology needed to improve implantation success rates in embryo transfer



Cell Therapy

Technology required for cell differentiation and quality control in cell therapy production



High-Content Screening

High-resolution imaging technology needed for screening drug candidates



References: The Insight Partners. Global Organoids Market Forecast, Frost&Sullivan, Fact.MR, Markets and Markets, Future Market Insights, Research and Markets, Stringent Datalytics

02. Expanding Applications of HT(1): Organoids*

•• Organoids as a new model in Advanced Bioindustry

Animal Testing Termination

USA(2022), EU(2025)

Organoid-based bio/pharmaceutical paradigm shift

Alternative R&D using organioids

Top 15 global bio/pharmas in preparation

Cell vs. Organoid





2D cell models	Category	3D organoid cell models
Sole	Cell type	**Multiple**
X	Intra-cell activities	**O**
Dish, plate, etc.	Growth platform	**3D Matrix**
Preliminary R&D, Drug test	R&D purpose	**Cancer, New Drug, Reg. Med.**

Limited cell-to-cell interaction and lack of biomimetic environment in 2D models

Realistic simulation of the biomimetic environment and accurate cell-to-cell interaction in 3D models

Application in healthcare



Broad applications in fields such as regenerative medicine and drug development within the bio-industry

* Organoid: tiny, self-organized three-dimensional tissue cultures that are derived from stem cells

02. Expanding Applications of HT(1): Organoids

•• Standardization of Organoid Analysis Using HT

Collaboration with Global Top Pharmas

Phenotypic Analysis of Organoid Cells Using AI-powered Holotomography

→ Signed a Joint Development Agreement with a Global Top-tier Pharmaceutical Company('25.01)

Establishing a Standard Protocol for Organoid Analysis Using 3D Label-free Imaging and AI



Reference: M. J. Lee et al., Experimental & Molecular Medicine (2024)

Collaborating w/ US-KOR Gov't Agencies

Selected for bio material developments

→ 3D organoids imaging device for new drug safety verification

Leading organoids R&D and QA/QC standardization

Korea		USA
Tomocube	Joint R&D	NIH NCATS
Ministry of Trade, Industry and Energy		
KBIO HEALTH. KAIST		

Joint R&D with NIH and its counterparts in Korea

Leading Standardization Efforts with Global Enterprises and Government Agencies

* NIH – National Institute of Health

02. Expanding Applications of HT(2): IVF

•• 3D Label-Free HT Imaging and AI for Selecting High-Implantation Embryos

Conventional Unmet Needs

- Label-free imaging is essential for embryo selection processes
- Prohibited to dye or edit genes during embryo selection process
- Current BF microscopy: high intra- and inter-clinician variability

Bright field microscope



Source : www.fao.org

HT-measured mouse embryo



Unique Technology for Label-Free Selection
→ 3D Label-free Holotomography

Synergies from strategic partnerships

Ovum selection using HT and Virtual Biomarkers

Big hospitals & institutions ⟷ Tomocube

Phototoxicity test for IRB approval using HT-X1 in human embryo studies



- 3D high-res. imaging from G1 phase to blastocyst (72 hours) confirmed
- AI-based embryo selection – 95% Accuracy (under review)

02. Expanding Applications of HT(3): Cell Therapy

•• Transformative Solution for Quality Control in Cell Therapy Manufacturing

HT powered analysis S/W allowing Improvements in cell therapeutics manufacturing



Non-invasive QC Process for Cell Therapy



First application expected for Parkinson's treatment using iPSC-derived stem cells

Potential for application across diverse cell therapies

02. Expanding Applications of HT(4): Drug Development

•• Application of HT in Phenotypic Drug Discovery (PDD)

Improving Phenotypic Drug Discovery with HT and AI

TDD Target-Based Drug Discovery

Known drug target → Target-based assay → Lead identification → Lead optimization → Preclinical trials → Clinical trials

New discovery approaches necessary for uncurable diseases

PDD Phenotypic Drug Discovery

Disease model → Phenotypic assay → Lead identification → Target identification → Lead optimization → Preclinical trials → Clinical trials

- Real-time cell/tissue reaction observations → Can confirm efficacies
- Suitable for multi-targeted complex diseases
- Able to develop First-in-class drugs despite uncertain molecule target

New drug approval using PDD methods

Roche's SMA(Spinal Muscular Atrophy) therapy Evrysdi(risdiplam)

0.2 bn. USD 2023 → CAGR 40.8% → 2.2 bn. USD 2030(E)

Entering new PDD markets using AI

feature extraction software → Applicable to drug screenings



- Decreasing time & cost by skipping staining and washing
- Not damaging the cells using label-free methods
- Accurate data from S/W driven HT

AI model-based feature extractor will be updated on TomoAnalysis' next generation products

PDD(Phenotypic Drug Discovery): uses empirical, target-agnostic lead generation to identify pharmacologically active molecules and novel therapeutics which work through unprecedented drug mechanisms.
TDD(Target-Based Drug Discovery): focused on a drug target, a gene product that provides a starting point for invention of a therapeutic which modulates its expression, function, or activity

02. Expanding Applications of HT(5): Non-Bio Industrial Use

•• Non-Destructive Testing: Key Challenges in Glass Substrate and TGV Manufacturing

Non-invasive 3D Inspection of Through Glass Via(TGV)

High-resolution 3D Inspection and measurement

As-is	Tomocube
 출처 : www.vitrion.com	

Tomocube competencies: **No damage to TGV** + **Overall structure and internal surface**

Laser modulation and internal crack testing

Improving glass substrate qualities by testing pre- and post- TGV status

As-is	Tomocube
	

Tomocube competencies: **Live monitoring of laser power status** + **Micro internal cracks check**

Effects

- High quality glass substrate
- Laser process optimization
- Real-time quality assurance
- Defect rate reduction

02. Expanding Applications of HT(5): Non-Bio Industrial Use

High-Throughput Metrology: Key Challenges in Hybrid Bonding and CMP Process Control

3D analysis of Wafer (Hybrid Bonding)

Improving advanced packaging by Hi-Res imaging of wafers

As-is	Tomocube
	
Difficult in 3D measurements (2 min)	3D high-res measurements (< 1 sec)

Tomocube competencies: **Contactless testing** + **Measurement speed improvement**

Post CMP Testing

Measuring surface roughness on wafers after CMP

As-is	Tomocube
	
50 μm x 50 μm to take (2 min)	100 μm x 100 μm to take (< 1 sec)

Tomocube competencies: **Total wafer roughness testing** + **Measurement speed improvement**

Effects

- **Chip yields improvement**
- **Productivity Increase**
- **Cost reduction**
- **Further technical expandability**

02. Expanding Applications of HT(5): Non-Bio Industrial Use

•• Continuous R&D enabling the expansions beyond semiconductor and display sectors

New product launching

HT-R1 (Alpha) demo model

July '24 HT-R1 (Alpha) rev.3 dev. complete

⌄⌄

Q3 '24 Aberration correction algorithm appl.

⌄⌄

2025 Products for Hybrid Bonding testing

⌄⌄

2026 HT-R1 launching

3D measurement modules & device

Early **Providing modules to machinery/device makers**

Tomocube → HT Modules → makers → Device → End-users

Lowering competition risks amongst device makers

Key Industrial Applications

OLED/microLED	3D structural measurement and inspection of ultra-fine display components
TGV	3D structural analysis and crack detection of TGVs in glass substrates
Wafer	Hybrid bonding inspection
AR/VR	3D structural analysis of Holographic Optical Elements

(HT-R1 module shipments to partner companies and clients to begin in 1H 2025)

Chapter 3.

Investment Highlights

01. Tomocube’s Key Success Factors
02. Proven Technology Excellence
03. Proven Commercial Viability
04. Global Expansion Strategy
05. Leading Localization in Bio Equipment Manufacturing
06. 3Q25 Financial Highlights

Tomocube

01. Tomocube's Success Factors

•• Advanced Deep Tech Innovator in Bio Industry

First Player

World's First Commercialization of 2nd Gen Holotomography



5 + yrs
Tech gaps

Global Player

Proven Market Penetration with Global References

63.5%
2023 Export Ratio

30+ markets
Distribution Networks

Tomocube

Sufficient Capitals

Investment from Major Global Companies and VCs

SBVA

Hanmi Science

...

KRW 44 bn. +
Capital raise

Rapid Growth

Revenue and profitability in high growth momentum

+85% yoy
Revenue
H1 '23 – H1 '24

51.9%
(2021~2023)
Sales CAGR

02. Proven Technological Excellence

•• Holotomography Recognition in Global Market

Tomocube is leading global technology developments

Holotomography featured in top publications by industry



Nature Photonics | Nature Cell Biology | Nature Methods | Nature Reviews Methods Primers

Competitive Impact Factor (IF)



Cumulated customer references to HT's market position

Steady increase in publications w/ Tomocube products



Main Research Areas



Virus | Cancer cell | Stem cell | Organoid

Driving new customer acquisition opportunities

Major International Collaborations and Conferences

Bioimaging, Organoids, Major Institutions
(MIT, Harvard, Mayo Clinic, University of Tokyo, Tsinghua University)



Continuous exposure as the new bio/healthcare technology

High Interest from Global Biopharma & Research Institutions

* : Impact Factor - a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

03. Proven Commercial Viability

•• HT Expected to Show Explosive Growth as Best-in-Class Technology

High satisfaction from customer base



More global customer references

+100 Major Global Customers (Universities, Research Institutes, Corporations)

# of Customers CAGR 27.3% (2019~2023)

Universities and Institutes			Industry
Johns Hopkins University	ETH Zurich		CJ
Seoul National University	MIT		LG Chem
OIST	US Air Force Lab	CHA Hospital	BAYER

A Continuously Growing Revenue Pipeline

Growth in New and Returning Customers



04. Global Expansion Strategy

•• Expansion of Direct Sales & Distribution Networks Globally

Global expansion + **Quality references** + **Extensive B/D and marketing**

Tomocube Europe

European subsidiary established in 2025.06

12 Distributors
UK, France, Germany, Italy, Poland, Spain and Portugal, Finland, Norway, Benelux, Israel, Czech, Romania

Tomocube APAC

Distribution Expansion

10 Distributors
Japan, China (Shanghai, Guangzhou, Hong Kong, Macao), Singapore, India, Taiwan, Thailand, Australia

Tomocube

Tomocube USA

Direct Sales & Distributor Expansion

2 distributors
US (Central), Chile

Key Opinion Leader (KOL) Acquisition in 2025

- US, Vanderbilt University Medical Center
- US, MD Anderson Cancer Center
- US, St. Jude Children's Research Hospital
- US, Wake Forest Institute of Regenerative Medicine
- Switzerland, ETH Zurich (Returning Customers)

Acquisition of Global KOL Customers → Enhanced Technology and Product Promotion in Academia and Industry

Global Marketing and Business Development

- Established Centers of Excellence
- Conference exhibition
- On-site demos
- Collaboration with distributors
- Social media / online PR

05. Leading Localization in Bio Equipment Manufacturing

•• Direct Beneficiary of Government's Bio Equipment Localization Policy

KR Government's subsidy on domestic device R&D 5% or less for cell analysis equipment and other device dev.

Ministry of Science and ICT

"20% or more to be domestically manufactured by 2027"

World-Class HT Technology

Tomocube's cumulative public funding history

Over KRW 12.5 bn. public R&D and subsidies since 2015

- 3D holography microscope
- Domestic device competencies improvement
- Biomedical technology
- ⋮

Ministry of Science and ICT · Ministry of Health and Welfare · Ministry of SMEs and Startups · Ministry of Trade, Industry and Energy



Selected for PPS's innovative device purchase

Public Procurement Service

"KRW 20.1 bn. worth purchase demand announcement"

Tomocube

HT-X1
5 units

Matching customers demands

- Seoul Natl. University
- Chonnam Natl. University
- Chungnam Natl. University
- Korea Basic Science Institute
- Korea Research Institute of Bioscience and Biotechnology

Completed Recognition of KRW 1.39 Billion Revenue for 2024

06. 3Q25 Financial Highlights

•• Summary Income Statement

- 3Q revenue KRW 2.52B (YoY +20.0%, QoQ -19.8%): HT-X1 Plus impact; QoQ down on absence of non-bio revenue
- GPM 62.1% (YoY +0.4%p, QoQ -6.2%p): margin down on absence of non-bio revenue
- Operating loss KRW 1.83B: widened on QoQ revenue decline
- Overseas revenue 79.8%: strong US/EU performance; EU mix up post-subsidiary launch (Jun '25)

Unit : million KRW

	3Q 25	3Q 24	YoY (%)	2Q 25	QoQ (%)
Sales	2,522	2,101	20.0	3,143	-19.8
Cost of Goods Sold	955	804	18.8	997	-4.2
Gross Profit	1,567	1,297	20.8	2,145	-27.0
GPM (%)	62.1	61.7		68.3	
SG&A	3,396	2,868	18.4	3,272	3.8
Operating Profit	-1,829	-1,571	-16.4	-1,126	-62.4
Net Profit (Loss)	-1,537	-1,565	1.8	-1,130	-36.0

Notes: Based on audited K-IFRS financial statements



06. 3Q25 Financial Highlights

•• Financial Statements

Statement of Financial Position

Unit : million KRW

Category	2022	2023	2024	3Q25
Current Assets	22,126	15,952	40,062	34,815
Non-Current Assets	2,930	3,823	3,548	6,222
Total Assets	**25,055**	**19,775**	**43,610**	**41,037**
Current Liabilities	52,198	1,776	1,328	2,265
Non-Current Liabilities	692	291	292	1,169
Total Liabilities	**52,890**	**2,067**	**1,620**	**3,434**
Capital Stock	1,100	2,612	6,523	6,627
Capital Surplus	-	66,720	97,882	100,164
Other Capital Items	4,713	5,610	3,069	1,739
Accumulated Other Comprehensive Income	21	-16	36	47
Retained Earnings (Deficit)	(33,668)	(57,218)	(65,520)	(70,974)
Total Equity	**(27,834)**	**17,708**	**41,990**	**37,603**

Notes: Based on audited K-IFRS financial statements.

Income Statement

Unit : million KRW

Category	2022	2023	2024	3Q25
Sales	**1,871**	**3,747**	**5,939**	**6,318**
Cost of Goods Sold	928	1,565	2,349	2,280
Gross Profit	943	2,182	3,590	4,037
Selling & Admin Expenses	**7,311**	**8,915**	**12,370**	**10,005**
Operating Profit	(6,369)	(6,733)	(8,780)	(5,967)
Financial Gains (Losses)	35,579	(16,889)	300	544
Other Gains (Losses)	126	71	177	(30)
Profit (Loss) Before Tax	29,336	(23,550)	(8,302)	(5,453)
Income Tax Expense	-	-	-	-
Net Profit (Loss)	**29,336**	**(23,550)**	**(8,302)**	**(5,453)**

Notes: Based on audited K-IFRS financial statements.

Appendix

01. Board of Directors
02. Key Personnel

Tomocube

01. Board of Directors

•• Independent, professional board with a focus on accountability

YongKeun Park Chairman of the Board, CEO

Education Ph.D. in Health Science and Technology, Harvard-MIT

Career
- Co-founder & CEO, Tomocube
- Professor, KAIST

Sang-Il Park Outside Director

Education Ph.D., Stanford University

Career
- CEO, Park Systems
- Founder & CEO, Park Scientific Instrument

Byung-Kyun Ham Outside Director

Education J.D., Seton Hall University School of Law

Career
- Dentons Lee Senior Attorney
- Law Firm Jipyeong Senior Foreign Lawyer
- General Counsel, Seegene
- attorney for the U.S. Department of Health and Human Services

Sang-Hoon Cha Outside Director

Education Ph.D., Seoul National University, Medicine

Career
- Multipurpose Synchrotron Radiation Construction Project Committee
- Central Pharmaceutical Affairs Council
- Professor, Department of Medicine, Chungbuk National University College of Medicine
- President, Osong Foundation for Advanced Medical Industry
- President, Korea Drug Development Fund

Sung-Ho Ko Inside Director, COO

Education M.S. in Industrial Engineering, KAIST

Career
- General Manager, Lutronic
- Country Manager, Samsung Medison

Young-seok Shin Auditor

Education M.S. , Beijing University, MBA

Career
- CFO, ASTech Co., Ltd.
- Director, Samjong KPMG LLC

02. Senior Executives

More than 10 years of experienced management and development personnel in the relevant field

YongKeun Park CEO

Education Ph.D. in Health Science and Technology, Harvard-MIT

Career
- Co-founder & CEO, Tomocube
- Professor, KAIST

Sung-Ho Ko COO

Education M.S. in Industrial Engineering, KAIST

Career
- General Manager, Lutronic
- Country Manager, Samsung Medison
- Quality Control, Daewoo Electronics

Taehong Kim SVP of Precision Division

Education B.S. in Electrical and Electronic Engineering, KAIST

Career
- Software Team Lead, Wiseplanet
- Software Engineer, Photon Dynamics Korea
- Acron, S/W team

Sumin Lee SVP of Life Science Division

Education Ph.D. in Life Sciences, POSTECH

Career
- R&D Project Planning, National Forensic Service
- Postdoctoral Researcher, POSTECH

Wan-Sung Ku CFO&CSO

Education Ph.D. (ABD) in Pharmacy, Sungkyunkwan University

Career
- CFO, Geninus
- Analyst, NH Investment & Securities
- Research Planning, Dong-A Socio Holdings


Tomocube